Literature DB >> 11528097

Direct-antiglobulin-test-negative immune haemolytic anaemia and thrombocytopenia in a patient with Hodgkin's disease.

H Kondo1, T Oyamada, A Mori, H Sumi, K Kurosu, E Kajii, A Mikata.   

Abstract

A case of direct-antiglobulin-test (DAT)-negative auto-immune haemolytic anaemia (AIHA) and immune thrombocytopenia (ITP) associated with Hodgkin's disease (HD) is reported. A 52-year-old male was admitted with anaemia, thrombocytopenia, and lymphadenopathy. The patient was DAT negative, although he exhibited the clinical features of warm-type AIHA and elevated levels of red-blood-cell-associated IgG (RBC-IgG). The serum level of platelet-associated IgG (PA-IgG) was markedly increased. A biopsy specimen of the inguinal lymph nodes showed HD of mixed cellularity. Marked improvement of subjective symptoms, normalization of haematological values and a decrease in the level of both RBC- and PA-IgG were observed after the start of combination chemotherapy for HD. Although the association of HD, ITP, and/or AIHA has been infrequently reported, the measurement of RBC-IgG is recommended in cases of HD with anaemia even though DAT is negative, since HD is known to be associated with various protean immunological abnormalities. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11528097     DOI: 10.1159/000046570

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  2 in total

1.  Utilisation of Flow-cytometry in the Diagnosis of Auto Immune Haemolytic Anaemia.

Authors:  Jitender Mohan Khunger; H P Pati; M Mahapatra; Arjun Khunger
Journal:  Indian J Hematol Blood Transfus       Date:  2018-10-05       Impact factor: 0.900

2.  A Case of Non-Hodgkin's Lymphoma in Patient with Coombs' Negative Hemolytic Anemia and Idiopathic Thrombocytopenic Purpura.

Authors:  So Yeon Park; Soyon Kim; Eun Sil Kim; Soon Uk Choi; Hee Jae Hyun; Ju Young Ahn; Ju Hyoung Lee; Seo Hee Ryu; Jae Hyun Park; Gyeong In Lee; Hyo Jin Lee
Journal:  Cancer Res Treat       Date:  2012-03-31       Impact factor: 4.679

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.